Group “nearmedic” (parent — OOO “nearmedic Plus”), which includes the pharmaceutical manufacturer and the network of clinics, beginning the search for a strategic investor. This was told by two sources in the pharmaceutical market; this is dedicated to a letter of investment proposal “nearmedic” sent to partners (at the disposal). The shareholders of the company including considering the possibility of transfer of control of the company, the letter said. The representative of “nearmedic” failed to respond promptly to the request .
The group of “nearmedic” includes a subsidiary, OOO “nearmedic Pharma” — the manufacturer of the antiviral agent “Kagocel”, which is the second biggest selling drug at pharmacies in Russia at the end of 2016, according to the DSM Group. According to the analytical Agency, it accounted for 26.6 percent of all sales in the market of antiviral drugs. In 2016, the volume of sales “Kagotsel” amounted to 5 billion rubles are Also in the “nearmedic” is a manufacturer of laboratory equipment.
On sale only subunits that are engaged in the production of drugs, diagnostic tests and laboratory equipment, from the presentation. The network of clinics “nearmedic” is not included in the proposals for the investor.
In 2012, the strategic investor “nearmedic Pharma” was the state Corporation RUSNANO. She received the accounting period by 34.45% of the company, investing about RUB 1.3 billion But a year later the Corporation abandoned the project and sold its stake head OOO “nearmedic Plus”. Investment returns amounted to about 41.1 percent, reported the state Corporation.
Now 100% head belongs to the Cypriot OOO “nearmedic international limited”, follows from the data register. According to the Cyprus registry, the main beneficiary of “Nearmedic” — the General Director of the company Vladimir Nesterenko, he owns 42,42% of the company. Even at 4.65% — his Deputy Anatoly Suslov. Son of the General Director and development Director of the company Sergey Nesterenko belongs to 3.66% of the company. The remaining shares are divided between individuals. 100% of the Cyprus company is in pledge at Bank VTB in March 2015 as security for a loan of 2.4 billion rubles, according to the materials of the registry. The pledge agreement will expire on 22 September 2022.
According to the company presentation for future investors, “nearmedic” plans to attract about $100 million (the size of offered share is not disclosed), to strengthen positions on the Russian market and expand business on the international level. A five-year business plan of the company includes the launch of seven new pharmaceutical projects in Russia and abroad, is celebrated there. The evaluation of the CEO IMS Health Russia of Nikolay Demidov, the whole group “nearmedic” can cost $250-350 million.
“Nearmedic” may be of interest to the investor, thanks to these “Kagocel”, said the General Director DSM Group Sergey shuljak. In such transactions the key acquisition becomes not production, but a brand that brings the main income. By 2020, “Kagocel” will occupy about 54% of all sales of “nearmedic”, predicts the company in a presentation.
The revenue of “nearmedic Plus” in 2015 amounted to 8.5 billion rubles, according to “SPARK-Interfax”. Net loss for the same period amounted to 26 million rubles.